推荐产品
等級
pharmaceutical primary standard
API 家族
bezafibrate
製造商／商標名
EDQM
應用
pharmaceutical (small molecule)
格式
neat
儲存溫度
2-8°C
SMILES 字串
CC(C)(Oc1ccc(CCNC(=O)c2ccc(Cl)cc2)cc1)C(O)=O
InChI
1S/C19H20ClNO4/c1-19(2,18(23)24)25-16-9-3-13(4-10-16)11-12-21-17(22)14-5-7-15(20)8-6-14/h3-10H,11-12H2,1-2H3,(H,21,22)(H,23,24)
InChI 密鑰
IIBYAHWJQTYFKB-UHFFFAOYSA-N
基因資訊
human ... PPARA(5465) , PPARD(5467) , PPARG(5468)
正在寻找类似产品? 访问 产品对比指南
一般說明
This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.
應用
Bezafibrate EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.
生化／生理作用
过氧化物酶体增殖物激活受体（PPAR）是类固醇核受体超家族成员之一。苯扎贝特是过氧化物酶体增殖物激活受体活化剂，用于PPARα、PPARδ和PPARγ。脂蛋白脂酶（LPL）激活剂。
PPARgamma激动剂（包括苯扎贝特）在抑制RSV感染期间的炎症反应中具有有益作用，因此在重度RSV感染过程中可能具有临床疗效。
PPARgamma激动剂（包括苯扎贝特）在抑制RSV感染期间的炎症反应中具有有益作用，因此在重度RSV感染过程中可能具有临床疗效。
包裝
The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.
其他說明
Sales restrictions may apply.
訊號詞
Warning
危險聲明
危險分類
Acute Tox. 4 Oral
儲存類別代碼
11 - Combustible Solids
水污染物質分類（WGK）
WGK 1
閃點（°F）
Not applicable
閃點（°C）
Not applicable
U de Faire et al.
Cardiovascular drugs and therapy, 11 Suppl 1, 257-263 (1997-05-01)
A large number of both primary and secondary preventive trials suggest that treatment of elevated plasma lipids may reduce the frequency of coronary heart disease (CHD) events. Meta-analyses indicate that for every 10% reduction of cholesterol, CHD mortality is lowered
R Manfredi et al.
The Journal of infection, 42(3), 181-188 (2001-09-08)
To assess the correlation between antiretroviral treatment and dyslipidaemia in HIV-infected patients, and the role of bezafibrate as a lipid-lowering agent. We retrospectively compared serum lipid levels of five groups of 40 patients, each of them treated with either saquinavir
U de Faire et al.
European heart journal, 17 Suppl F, 37-42 (1996-12-01)
Current experience from coronary angiographic trials using different treatment regimens such as lifestyle changes, resins, nicotinic acid and statins, shows that progression of atheroma can be retarded, and that regression can sometimes be induced, by a marked lowering of LDL-cholesterol.
Bezafibrate derivatives as potent effectors of hemoglobin.
C Poyart et al.
Methods in enzymology, 232, 496-513 (1994-01-01)
D Ståhlberg et al.
European journal of clinical pharmacology, 40 Suppl 1, S33-S36 (1991-01-01)
The influence of bezafibrate treatment on hepatic cholesterol metabolism was studied in rats and in humans. The activities of the three key enzymes involved in cholesterol metabolism [3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase, cholesterol 7 alpha-hydroxylase, and acyl-coenzyme A: cholesterol acyltransferase
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系技术服务部门